Dec 4, 2018 Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma Learn More
Nov 13, 2018 Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update Learn More
Nov 12, 2018 Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies Learn More
Oct 2, 2018 Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma Learn More